该研究旨在确定PD-L1（程序性细胞凋亡配体1）表达和肿瘤浸润淋巴细胞（TILs）在三阴乳腺癌（TNBC）中的预后意义。本研究检测未接受新辅助治疗的TNBC患者的PD-L1表达和TIL百分比。分析PD-L1表达和TIL百分比与生存率之间的关系。鉴定≥ 1％ PD-L1表达肿瘤中PD-L1阳性肿瘤浸润免疫细胞（TIICs）的存在作为一种新的PD-L1评估参数。在PD-L1阳性病例中，PD-L1阳性TIICs的存在作为一个新的参数可显著提高总体生存率。TIL百分比在整体生存率和远处转移生存率中均增加（p = 0.040和p = 0.006，分别）。结果发现，在没有肿瘤内PD-L1阳性TIICs的患者中，死亡风险增加5.18倍（p = 0.013）。TIL百分比≤ 10％的患者，其死亡风险计算为比TIL百分比> 40％的患者高5.40倍（p = 0.024），并计算出远处转移风险增加11.95倍。本研究发现TIL百分比在TNBC生存中具有显著差异。PD-L1阳性病例中肿瘤内PD-L1阳性TIICs的存在显著提高生存率。

This study aims to determine the prognostic significance of programmed cell death ligand 1 (PD-L1) expression and tumour-infiltrating lymphocytes (TILs) in triple- negative breast cancer (TNBC). PD-L1 expression and TIL percentage were determined in TNBCs that did not receive neoadjuvant therapy. The relationship between PD-L1 expression and the percentage of TILs with survival was investigated. The presence of intratumoural PD-L1-positive tumour-infiltrating immune cells (TIICs) in tumours with ≥ 1% PD-L1 expression was identified as a new PD-L1 evaluation parameter. The presence of intratumoural PD-L1-positive TIICs as a new parameter in PD-L1-positive cases increased overall survival. The percentage of TILs increased in both overall and distant metastasis-free survival (p = 0.040 and p = 0.006, respectively). As a result, it was found that the risk of death was increased 5.18-fold (p = 0.013) in patients without intratumoural PD-L1-positive TIICs. This risk of death was calculated to be 5.40-fold higher in patients with TIL percentage ≤ 10% than in those with > 40% (p = 0.024), and the risk of distant metastasis was calculated to be 11.95 times higher. In our study, we discovered that the percentage of TILs made a statistically significant difference in TNBC survival. The presence of intratumoural PD-L1-positive TIICs in PD-L1-positive cases significantly increased survival.